S
Stephen Harrow
Researcher at Beatson West of Scotland Cancer Centre
Publications - 51
Citations - 2713
Stephen Harrow is an academic researcher from Beatson West of Scotland Cancer Centre. The author has contributed to research in topics: Medicine & SABR volatility model. The author has an hindex of 11, co-authored 31 publications receiving 1306 citations.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +21 more
TL;DR: SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death.
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Posted ContentDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time, and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Gerard G Hanna,Louise Murray,R. Patel,Suneil Jain,K. Aitken,Kevin Franks,N. van As,Alison Tree,P. Hatfield,Stephen Harrow,Fiona McDonald,Munaza Ahmed,Frank Saran,G. Webster,Vincent Khoo,David Landau,David J. Eaton,Maria A. Hawkins +17 more
TL;DR: Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints and it is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between S ABR studies and internationally.
Journal ArticleDOI
Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,L. Mulroy,Michael Lock,G. Rodrigues,Brian Yaremko,D. Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,S. Senthi,M. Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +19 more